# Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Source: https://onco.cc/trials/nct05737706/  
OnCo record `nct05737706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MRTX1133 in Non-small-cell lung cancer and Rectal cancer, run by Mirati Therapeutics Inc., recorded as terminated on the registry.

## Summary

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation is a phase 1 interventional study registered as NCT05737706 by Mirati Therapeutics Inc., with 63 participants recorded, started 2023-03-06 and due to reach its primary completion in 2025-03-10. Interventions recorded: MRTX1133. Conditions recorded: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma.

Linked to the drug MRTX1133 because the registry names it among its interventions and Non-small-cell lung cancer and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05737706
- Phase: 1
- Setting: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT05737706: https://clinicaltrials.gov/study/NCT05737706

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [MRTX1133](https://onco.cc/drugs/mrtx1133/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05737706.json